Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claudia P Miller

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2011
Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine gliomaBarbara S Paugh, Alberto Broniscer, Chunxu Qu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 25, 2024
US Food and Drug Administration Approval Summary: Eflornithine for High-Risk Neuroblastoma After Prior Multiagent, Multimodality TherapyElizabeth S Duke, Diana Bradford, Arup K Sinha, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2023
FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth SpectrumSonia Singh, Diana Bradford, Xiaoxue Li, et al.
The Oncologist|July 6, 2024
FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutationsGautam U Mehta, Paz J Vellanki, Yi Ren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 23, 2023
FDA Approval Summary: Dabrafenib in Combination with Trametinib for BRAFV600E Mutation-Positive Low-Grade GliomaMichael I Barbato, Jeannette Nashed, Diana Bradford, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2025
FDA Approval Summary: Vorasidenib for IDH-mutant Grade 2 Astrocytoma or Oligodendroglioma following surgeryMichael I Barbato, Amy K Barone, Stephanie L Aungst, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 21, 2022
FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease-Associated TumorsJaleh Fallah, Michael H Brave, Chana Weinstock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2024
FDA Approval Summary: Repotrectinib for Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung CancerMichael I Barbato, Diana Bradford, Yi Ren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2025
FDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAF-Altered Pediatric Low-Grade GliomaSonia Singh, Diana Bradford, Somak Chatterjee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 27, 2025
FDA Approval Summary: Datopotamab deruxtecan-dlnk for treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancerMelanie Royce, Mirat Shah, Lijun Zhang, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2011
Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine gliomaBarbara S Paugh, Alberto Broniscer, Chunxu Qu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 25, 2024
US Food and Drug Administration Approval Summary: Eflornithine for High-Risk Neuroblastoma After Prior Multiagent, Multimodality TherapyElizabeth S Duke, Diana Bradford, Arup K Sinha, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2023
FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth SpectrumSonia Singh, Diana Bradford, Xiaoxue Li, et al.
The Oncologist|July 6, 2024
FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutationsGautam U Mehta, Paz J Vellanki, Yi Ren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 23, 2023
FDA Approval Summary: Dabrafenib in Combination with Trametinib for BRAFV600E Mutation-Positive Low-Grade GliomaMichael I Barbato, Jeannette Nashed, Diana Bradford, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2025
FDA Approval Summary: Vorasidenib for IDH-mutant Grade 2 Astrocytoma or Oligodendroglioma following surgeryMichael I Barbato, Amy K Barone, Stephanie L Aungst, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 21, 2022
FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease-Associated TumorsJaleh Fallah, Michael H Brave, Chana Weinstock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2024
FDA Approval Summary: Repotrectinib for Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung CancerMichael I Barbato, Diana Bradford, Yi Ren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2025
FDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAF-Altered Pediatric Low-Grade GliomaSonia Singh, Diana Bradford, Somak Chatterjee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 27, 2025
FDA Approval Summary: Datopotamab deruxtecan-dlnk for treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancerMelanie Royce, Mirat Shah, Lijun Zhang, et al.
Pageof 3